Drugs / BAFF CAR-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06916767 | Jul 2025 → Dec 2027 expected | B-cell chronic lymphocytic leukemia | Paolo Caimi, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT05312801 | Nov 2023 → May 2025 overdue | B-cell non-Hodgkin lymphoma | Luminary Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAFF CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05312801 ↗ |
| Known as | LMY-920 | “BAFF CAR-T cells, LMY-920” NCT06916767 ↗ |
| Action | Deplete | “to eliminate malignant B cells” NCT05312801 ↗ |
| Modality | Cell therapy | “Autologous CAR-T cell therapy consisting of autologous cluster of differentiation 4 (CD4) positive and cluster of differentiation 8 (CD8) positive human T cells” NCT05312801 ↗ |